Adelaide, Australia, 24th November 2021 – GPN Vaccines is pleased to announce the appointment of Professor Paul Rolan as the Company's Chief Medical Officer. This appointment will significantly strengthen the executive team in preparation for the Company's upcoming first-in-human clinical trial. Prof Rolan is a clinical pharmacologist, pharmaceutical physician...
Adelaide, Australia, 24th November 2021 – GPN Vaccines announces the retirement of Dr Mohammed Alsharifi and Mr Martin Gotting from the Board of Directors and their appointment to key operational roles. At the conclusion of yesterday’s AGM Dr Mohammed Alsharifi and Mr Martin Gotting retired from the GPN Vaccines...
Adelaide, Australia, 30th June 2020 – Australian biotechnology company GPN Vaccines, which is developing a vaccine against the world’s foremost bacterial pathogen, Streptococcus pneumoniae, is pleased to announce it has raised A$7 million (USD$4.9 million) in an oversubscribed Series A2 investment round. GPN Vaccines has created...
Adelaide, Australia, 25 May 2020 – GPN Vaccines is pleased to announce Dr Ismail Kola has joined the Company’s Board of Directors. Dr Kola is a Senior Partner at Forepont Capital, a New York-based venture capital firm investing in pharmaceutical and biotechnology companies that improve healthcare outcomes....
Adelaide, Australia, 6 May 2020 – GPN Vaccines is pleased to announce Dr Gladys Monroy has joined the Company’s Scientific & Advisory Board. Dr Monroy is a world-leading intellectual property lawyer with expertise in strategic counselling and comprehensive patent portfolio management in the life sciences sector....
Adelaide, Australia, 11th April 2020 – GPN Vaccines is pleased to announce it has been awarded $1 million from the South Australian Government’s Research, Commercialisation and Startup Fund (RCSF) to support a first in human clinical trial on the Company's broad-spectrum pneumonia vaccine. Established in 2019,...